The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Abstract Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, Mark Cutler, David Cooper, Philip R. Dormitzer, Pei-Yong Shi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/ec866784239c40d8b7031906e2ca7586
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.